ZHONGFU Pharmaceutical

Zhongfu Pharmaceutical (Nanjing) is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company's lead candidate, ZF-001, is a highly selective thyroid hormone receptor beta (THR-β) agonist currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and related metabolic disorders. By targeting THR-β, Zhongfu aims to address the underlying lipid metabolism issues and liver inflammation associated with NASH while minimizing systemic side effects. The company's pipeline also includes early-stage programs targeting other metabolic and endocrine pathways. Zhongfu is positioned as a key player in the emerging Chinese landscape for metabolic drug development.